Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 23231510)

1.

Energy restriction: stepping stones towards cancer therapy.

Omar HA, Berman-Booty L, Weng JR.

Future Oncol. 2012 Dec;8(12):1503-6. doi: 10.2217/fon.12.142. Review. No abstract available.

2.

Energy deregulation: licensing tumors to grow.

Garber K.

Science. 2006 May 26;312(5777):1158-9. No abstract available.

PMID:
16728625
3.

Cell cycle and energy metabolism in tumor cells: strategies for drug therapy.

Amoedo ND, El-Bacha T, Rodrigues MF, Rumjanek FD.

Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):15-25.

PMID:
21110821
4.

Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents.

Ralph SJ, Low P, Dong L, Lawen A, Neuzil J.

Recent Pat Anticancer Drug Discov. 2006 Nov;1(3):327-46. Review.

PMID:
18221044
5.

Metabolic targeting of malignant tumors: small-molecule inhibitors of bioenergetic flux.

Mathupala SP.

Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):6-14. Review.

6.

Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.

Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO.

Br J Cancer. 2010 Jan 5;102(1):1-7. doi: 10.1038/sj.bjc.6605457. Epub 2009 Nov 24. Review.

7.

Antitumor effects of energy restriction-mimetic agents: thiazolidinediones.

Omar HA, Salama SA, Arafa el-SA, Weng JR.

Biol Chem. 2013 Jul;394(7):865-70. doi: 10.1515/hsz-2013-0139. Review.

PMID:
23612598
8.

Energy restriction as an antitumor target of thiazolidinediones.

Wei S, Kulp SK, Chen CS.

J Biol Chem. 2010 Mar 26;285(13):9780-91. doi: 10.1074/jbc.M109.065466. Epub 2010 Jan 21.

9.

PARP inhibitors refocus for rebound.

Schmidt C.

Cancer Discov. 2012 Aug;2(8):659. doi: 10.1158/2159-8290.CD-ND2012-030. Epub 2012 Jul 12. No abstract available.

10.

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Fauzee NJ, Pan J, Wang YL.

Pathol Oncol Res. 2010 Dec;16(4):469-78. doi: 10.1007/s12253-010-9266-6. Epub 2010 Apr 12. Review.

PMID:
20383759
11.

Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways.

Aziz K, Nowsheen S, Georgakilas AG.

Curr Mol Med. 2010 Oct;10(7):626-39. Review.

PMID:
20712589
12.

Tumor cell metabolism: cancer's Achilles' heel.

Kroemer G, Pouyssegur J.

Cancer Cell. 2008 Jun;13(6):472-82. doi: 10.1016/j.ccr.2008.05.005. Review.

13.

Network pharmacology for cancer drug discovery: are we there yet?

Azmi AS.

Future Med Chem. 2012 May;4(8):939-41. doi: 10.4155/fmc.12.44. No abstract available.

14.

The 11th International Congress on Targeted Anticancer Therapies Paris, 4-6 March 2013 (TAT 2013).

Samoilenko O, Zaletok S.

Exp Oncol. 2013 Sep;35(3):231-5. No abstract available.

PMID:
24084465
15.
16.

Targeting of cancer energy metabolism.

Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreño-Fuentes L, Moreno-Sánchez R.

Mol Nutr Food Res. 2009 Jan;53(1):29-48. doi: 10.1002/mnfr.200700470. Review.

PMID:
19123180
17.
18.

Targeting the human kinome for cancer therapy.

Daly RJ.

Crit Rev Oncog. 2012;17(1):vi-vii. No abstract available.

PMID:
22471667
19.

Metabolic targets for cancer therapy.

Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G.

Nat Rev Drug Discov. 2013 Nov;12(11):829-46. doi: 10.1038/nrd4145. Epub 2013 Oct 11. Erratum in: Nat Rev Drug Discov. 2013 Dec;12(12):963.

PMID:
24113830
20.

Protein kinase inhibitors as a therapeutic modality.

Levitzki A.

Acc Chem Res. 2003 Jun;36(6):462-9. Review.

PMID:
12809533
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk